Status:
COMPLETED
Once a Day (QD) - Twice a Day (BID) Clinical Trial: Didanosine, Lamivudine and Efavirenz Versus Zidovudine, Lamivudine and Efavirenz in the Starting Treatment of HIV
Lead Sponsor:
Clinical Trial Agency of HIV Study Group
Conditions:
HIV Infections
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
The purpose of this study is to compare the antiviral activity of two treatment groups for HIV chronic infection: a QD regimen of didanosine, lamivudine and efavirenz versus a BID regimen of zidovudin...
Detailed Description
The inhibition of HIV replication mediated by HAART causes an actual immunological reconstitution that has been clinically evidenced as a dramatic reduction in mortality, incidence of opportunistic di...
Eligibility Criteria
Inclusion
- Chronic HIV infection with plasma RNA viral burden of HIV \> 2,000 copies/ml obtained in the month prior to randomization.
- Ages 18 years or older.
- Women with childbearing potential should use an effective contraceptive method.
- The subjects should give their written informed consent.
- The subjects should provide the baseline laboratory values measured during the 4 weeks prior to the start of the study drugs, specified below:
- serum creatinine \< 1.5 times the upper normal limit;
- total amylase \< 1.4 times the upper normal limit;
- liver enzymes (AST, ALT) \< 4 times the upper normal limit.
Exclusion
- Previous antiretroviral treatment.
- Suspected (acute) primary HIV infection starting less than six months before.
- Suspected or proven acute hepatitis in the 30 days prior to inclusion in the study. Subjects with chronic hepatitis are eligible provided their liver function enzymes \< 4 times the upper normal limit.
- Previous therapy with agents with a significant potential of systemic myelosuppression, neurotoxicity, pancreatotoxicity, liver toxicity or cytotoxicity in the 3 months prior to the start of the study, or expected need for requiring therapy on inclusion, or therapy with methadone or ribavirin/interferons or treatment with neurotoxic drugs or drugs affecting CYP 3A4.
- Patients under methadone program
- Abuse of alcohol or drugs, sufficient, in the investigator's opinion, to prevent an adequate compliance with the study treatment or that could increase the risk of developing pancreatitis or toxic hepatitis.
- Untreatable diarrhea (\> 6 loose stools/day for at least 7 consecutive days) within the 30 days prior to inclusion in the study.
- Pregnancy or nursing.
- History of bilateral peripheral neuropathy or signs and symptoms of bilateral peripheral neuropathy \> Grade 2 on screening.
- Inability to tolerate oral drugs.
- Any other clinical condition or previous therapy that, in the investigator's opinion, leads the patient to be inadequate for the study or unable to comply with the dosage requirements.
Key Trial Info
Start Date :
June 1 2004
Trial Type :
INTERVENTIONAL
End Date :
November 1 2006
Estimated Enrollment :
360 Patients enrolled
Trial Details
Trial ID
NCT00256828
Start Date
June 1 2004
End Date
November 1 2006
Last Update
October 16 2007
Active Locations (57)
Enter a location and click search to find clinical trials sorted by distance.
1
Hospital Universitario de San Juan de Alicante
Alicante, Alicante, Spain, 03550
2
Hospital General de Área de Elda
Elda, Alicante, Spain, 03600
3
Hospital de Orihuela-Vega Baja, San Bartolomé-Orihuela
Orihuela, Alicante, Spain, 03314
4
Hospital Son Dureta
Palma de Mallorca, Balearic Islands, Spain, 07014